/
Oncology
Melanoma
241
Pipeline Programs↗
366
Active Trials↗
160
Companies Involved↗
Melanoma is a highly competitive landscape with 241 programs across 160 companies. The most active players are Merck & Co., Shanghai Juncell Therapeutics, Pfizer. 49 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical57
Phase 144
Phase 291
Phase 349
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
139 of 193 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 193 classified programs, each share of the total. Modality classified for 95% of 241 pipeline programs.
Analysis
Trial Status
1,796
clinical trials
Completed867 · 48%
Terminated297 · 17%
Recruiting167 · 9%
Unknown status167 · 9%
Active, not recruiting150 · 8%
Withdrawn75 · 4%
Other73 · 4%
Clinical Trials
Trial Activity
1796 trials
Page 1 of 120
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)